Methods for treating liver disorders using FXR agonists

A method for treating a condition mediated by Farnesoid X receptor (FXR), comprising administering to a subject a compound of Formula (I)

• or a stereoisomer, an enantiomer, a pharmaceutically acceptable salt thereof, an amino acid conjugate or acyl glucuronide conjugate thereof, at a dose of about 3 μg to about 100 μg;
• wherein said amino acid conjugate or acyl glucuronide conjugate is selected from:
• 2-({2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclor[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazol-6-yl}formamido)acetic acid;
• 2-({2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclor[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazol-6-yl}formamido)ethane-1-sulfonic acid;
• and
• (2S,3S,4S,5R,6S)-6-((2-((1R,3S,5S)-3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-fluorobenzo[d]thiazole-6-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid;
• and
• wherein said condition mediated by FXR is primary biliary cholangitis (PBC).